Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive interim Phase 2 data in generalized myasthenia gravis (gMG); on-track to enroll first patient for registrational Phase 3 portion of trial by year-end 2025 Strengthened financial flexibility with up to $150M loan facility to support the continued advancement of the Company’s late-stage indications in gMG and SPS, while also accelerating pre-launch activities EMERYVILLE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the...

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. “We continued to advance our lead program, TNX-103, in patients with PH-HFpEF and remain on track to enroll 230 patients in the ongoing Phase 3 LEVEL...

Company Updates FY 2025 Revenue Guidance from $111.0 Million to $113.0 Million to approximately $104.0 Million FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial and Operational HighlightsRevenues decreased 4% to $25.1 million, compared to $26.3 million for the same quarter of 2024. Gross profit decreased 10% to $13.6 million (54% of revenues), compared to $15.2 million (58% of revenues) for the same quarter of 2024. GAAP net loss totaled $2.0 million, compared to GAAP net loss of $1.4 million for the same quarter of 2024. Adjusted EBITDA1 totaled $3.5 million (14% of revenues), compared to $4.5 million (17% of revenues) for the same quarter...

– Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP – – Raised $225 million of financing, including $25 million private placement with Sanofi – – Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer – – Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 – – New reports of first-line pancreatic cancer patients with excellent responses to atebimetinib + FOLFIRINOX, including a patient with a complete response and a responding patient who was able to advance to radiation and surgery with curative intent – – Conference call scheduled for today, November...

Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced multiple recombinant protein programs toward commercialization Achieved key development and commercial milestones across life sciences and nutrition markets First purchase order received in cell culture media and molecular biology reagent segments Secured ERS Genomics CRISPR license to optimize production and product performance Strengthened liquidity and cash position through the completion of equity offering Cash, cash equivalents, restricted cash and cash equivalent, and investment grade securities of $10.4 million as of September 30, 2025 Dyadic to host an earnings call at 5:00 pm ETJUPITER, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE)...

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the third quarter ended September 30, 2025. Third Quarter 2025 vs. Third Quarter 2024 Financial SummaryGross revenue for the quarter was $0.6 million, compared to $0.2 million a year ago. Net revenue for the quarter, after accounting for one-time concessions, was negative $(0.1) million, compared with $0.2 million a year ago Operating expenses were $5.1 million, compared to $3.8 million a year ago. Net loss was $5.2 million, or $0.38 per share, compared to a loss of $3.4 million, or $0.31 per share a year ago. Adjusted EBITDA Loss of $4.1 million (non-GAAP measure as defined below), compared with $2.9...

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 ORKA-001 Phase 2a trial enrolling well with data expected 2H 2026 MENLO PARK, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported third quarter 2025 financial results and provided a corporate update. “We had a very successful quarter where we released our...

Bank continues to champion financial discipline and initiatives that strengthen the local community LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) — FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced financial results for the third quarter ending September 30, 2025. The bank reported the following:Net income was $216.4 million Total deposits were $23.2 billion Net loans were $16 billion Total assets were $26.7 billionFirstBank’s net income experienced a 37 percent increase year-over-year from $157.65 million in Q3 2024 to $216.42 million in Q3 2025. In addition, the bank announced an agreement to be acquired by PNC one of the largest diversified financial institutions in the U.S. The transaction, which remains subject to regulatory approvals and customary closing conditions,...

The Board of Directors has today approved the interim report for the period 1 January – 30 September 2025. COPENHAGEN AIRPORTS A/SP.O. Box 74Lufthavnsboulevarden 6DK-2770 Kastrup Contact:Rasmus LundCFO Telephone: +45 32312800E-mail: cphpresse@cph.dkwww.cph.dkCVR no. 14 70 72 04AttachmentsInterim report of Copenhagen Airports A-S (CPH) for the period 1 January – 30 September 2025Q3 2025 Interim Report of Copenhagen Airports UK

ALK delivers 18% global organic revenue growth with operating profit up 41% in Q3 Results were better than expected, driven by a strong momentum for tablets, adrenaline autoinjectors, and SCIT/SLIT-drops. Operating profit increased as sales growth, improved gross margin, and optimisations yielded a profit margin of 28%. The full-year outlook has been upgraded.     Q3 performance highlights Comparative figures for Q3 2024 are shown in brackets. Growth rates are stated in local currencies (l.c.), unless otherwise indicated.Total revenue increased by 18% to DKK 1,530 million (1,313) on double-digit sales growth in all regions.     Tablet sales grew by 17% to DKK 737 million (634), on higher volumes. Europe and North America delivered growth of 23% and 20%, respectively. International markets reported a 4% decrease and was impacted by phasing...